Oral Azacitidine for Maintenance Treatment of Acute Myeloid Leukaemia After Induction Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

The National Institute for Health and Care Excellence (NICE) invited the manufacturer (Celgene) of oral azacitidine (ONUREG), as part of the Single Technology Appraisal (STA) process, to submit evidence for the clinical effectiveness and cost-effectiveness of oral azacitidine for maintenance treatme...

Descripción completa

Detalles Bibliográficos
Autores principales: Witlox, Willem, Grimm, Sabine, Howick, Jeremy, Armstrong, Nigel, Ahmadu, Charlotte, McDermott, Kevin, Otten, Thomas, Noake, Caro, Wolff, Robert, Joore, Manuela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10322744/
https://www.ncbi.nlm.nih.gov/pubmed/37129774
http://dx.doi.org/10.1007/s40273-023-01272-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10322744/
https://www.ncbi.nlm.nih.gov/pubmed/37129774
http://dx.doi.org/10.1007/s40273-023-01272-9

Ejemplares similares